Please login to the form below
Roche, J&J and Novartis in hepatitis C diagnostics tie-up
Roche signs licensing agreements for Hepatitis C immunodiagnostics with J&J subsidiary Ortho-Clinical Diagnostics and Novartis
Swiss-based pharmaceutical group Roche has signed licensing agreements for Hepatitis C immunodiagnostics with J&J subsidiary Ortho-Clinical Diagnostics and Swiss-headquartered Novartis.
Roche, Ortho-Clinical and Novartis also agreed to settle all litigation related to licensed patents.
Roche will receive a worldwide royalty-bearing license under the deal, according to a Roche statement. Financial terms were not disclosed.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Digital account director
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- FDA leaders offer perspective on accelerated approval of Biogen’s Aduhelm
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- UK’s CMA fines drugmakers £260m for overcharging NHS for steroid med
- Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
PMHub
TRIDUCIVE
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
